{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T14:28:01Z","timestamp":1649168881099},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/01.nurse.0000334643.44337.3c","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T16:37:18Z","timestamp":1377880638000},"page":"26-32","source":"Crossref","is-referenced-by-count":2,"title":["These \u201csmart weapons\u201d hit cancer in novel ways"],"prefix":"10.1097","volume":"38","author":[{"given":"Jeanne","family":"Held-Warmkessel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"7","key":"R2-30-20210130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1470-2045(03)01137-9","article-title":"Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer","volume":"4","author":"Sridhar","year":"2003","journal-title":"The Lancet Oncology"},{"issue":"9","key":"R3-30-20210130","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Annals of Oncology"},{"issue":"10","key":"R4-30-20210130","first-page":"803","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews","volume":"6","author":"Lacouture","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"R5-30-20210130","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1188\/04.CJON.654-656","article-title":"Severe acneiform rash","volume":"8","author":"Yamamoto","year":"2004","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"2","key":"R6-30-20210130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1188\/04.CJON.163-168","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors","volume":"8","author":"Krozely","year":"2004","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"22","key":"R8-30-20210130","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: Is there a silver lining","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"R9-30-20210130","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Jr, et al. Epidermal growth factor receptor-inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management","volume":"12","author":"Lynch","year":"2007","journal-title":"Oncologist"},{"issue":"5","key":"R10-30-20210130","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR Inhibitor Rash Management Forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"The Oncologist"},{"issue":"3","key":"R11-30-20210130","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1188\/05.CJON.332-338","article-title":"Cetuximab: Adverse event profile and recommendations for toxicity management","volume":"9","author":"Thomas","year":"2005","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"5","key":"R12-30-20210130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jjco\/hyl021","article-title":"Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs","volume":"36","author":"Niho","year":"2006","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"3","key":"R13-30-20210130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0749-2081(03)00045-7","article-title":"Trends in cancer therapy: Role of monoclonal antibodies","volume":"19","author":"Schmidt","year":"2003","journal-title":"Seminars in Oncology Nursing"}],"container-title":["Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.NURSE.0000334643.44337.3c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:15:36Z","timestamp":1620933336000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00152193-200809000-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/01.nurse.0000334643.44337.3c","relation":{},"ISSN":["0360-4039"],"issn-type":[{"value":"0360-4039","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}